08:25 AM EDT, 08/08/2025 (MT Newswires) -- Spectral Medical ( EDTXF ) on Friday said its second-quarter net loss narrowed as operating expenses fell, primarily due to finance income on a promissory note issued in May.

Net loss narrowed to $1.9 million, or nil per share, compared with a loss of $4.4 million, or $0.02 per share, for the same period in the prior year.

Revenue increased 73% to $813,000 over the same period.

Spectral said it is on track to report topline results from its Tigris trial in the third quarter. Tigris is a Phase III trial evaluating PMX for the treatment of endotoxic septic shock. The results of this study are expected to support Spectral's Premarket Approval (PMA) submission to the U.S. Food and Drug Administration.

"We are now in the final stages of data analysis following the completion of follow-up for the final patient in Tigris," said Dr John Kellum, chief medical officer. "We continue to believe in the strong clinical potential of PMX to reduce mortality in patients with endotoxic septic shock, and we look forward to sharing topline results soon."